Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking - 2003 -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (124)	1/18/2003 4:31:36 AM
From: John Metcalf	Read Replies (1) \| Respond to of 383

Bernard (Jibacoa) was running away a week ago, up 26%. As a technician, he probably picked stocks on a more timely basis than the rest of us. This makes me even more likely to follow his lead as the year unfolds. The un-reality of a stock-picking contest becomes more obvious. If any of us could sell our portfolios now and stand pat for the duration, after last year's winners with no gains, who would not do so? If not, why not? Which stocks would anyone hold if they could sell the rest in the contest? Which would anyone sell? As to the aforementioned ELN, I have it too and think that $10 is a minimal sell price.

To: Arthur Radley who wrote (124)	1/22/2003 8:09:43 AM
From: Arthur Radley	Respond to of 383

Several of "you" have MLNM in your portfolios....good luck with this news today and those suffering from this disease. Millennium Submits New Drug Application for VELCADE(TM) (Bortezomib) for Injection Wednesday January 22, 7:59 am ET -- Novel therapy also granted Orphan Product Designation -- CAMBRIDGE, Mass., Jan. 22 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM - News) today announced that it has submitted a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market VELCADE as a treatment for relapsed and refractory multiple myeloma. In June 2002, VELCADE was granted fast-track status by the FDA as having the potential to treat a serious, life- threatening condition and address an unmet medical need. The NDA was submitted under the provisions of Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses.

To: Arthur Radley who wrote (124)	1/29/2003 10:14:02 AM
From: scott_jiminez	Read Replies (1) \| Respond to of 383

Yeah, perhaps its time to join a monastery. But everything is tanking now. The only thing that makes sense to me right now is the bizarre: how about a company with a record of responding very favorably in a precisely analogous environment in Kuwait a decade ago. One example I just found has the completely reasonable name of 'Boots and Coots' (symbol: WEL). And just what does Boots and Coots do? Put out oil well fires...